OMCL Stock Recent News
OMCL LATEST HEADLINES
Butterfly Network and Omnicell emerge as standout health tech stocks as AI and quantum breakthroughs reshape diagnostics and medication management.
The average of price targets set by Wall Street analysts indicates a potential upside of 39.4% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The consensus price target hints at a 34.2% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI® (metoclopramide) nasal spray, together with EVERSANA, a leading provider of global commercial services to the life sciences industry, today announced the addition of Omnicell (NASDAQ: OMCL), a leader in medication management and fulfillment.
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Appoints Baird Radford as Executive Vice President and Chief Financial Officer.
Omnicell, Inc. (NASDAQ:OMCL ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President of Investor Relations Nchacha E. Etta - Executive VP & CFO Randall A.
The mean of analysts' price targets for Omnicell (OMCL) points to a 44.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Omnicell's service business is rapidly growing, now 22% of revenue, outpacing industry trends and supporting long-term upside. My updated DCF analysis yields a price target of $57.46, representing 93% upside, with Wall Street consensus trailing behind. The primary risk is the pace of transition from product to service revenue, but a strong backlog mitigates margin and cash flow concerns.
Omnicell (OMCL) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.51 per share a year ago.